ERGOTAMINE TARTRATE | A087693 | PANGEA PHARMACEUTICALS LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Senores Pharmaceuticals, Inc. FDA-2026-P-7182 · 6 docket documents Senores Pharmaceuticals, Inc. filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Ergotamine Tartrate Sublingual Tablets 1 mg suitable for submission in an Abbreviated New Drug Application, based on the reference list | Suitability | 2026-06-29 | Open | Senores Pharmaceuticals, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$42.77
per ea
Lowest NADAC/Unit
$42.77
per ea
Brand NDCs
0
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 81279010420ERGOMAR 2 MG TABLET SUBLINGUAL | $42.77 | EA | — | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.